Aspira Womens Health (FRA:CUL) 3-Year Book Growth Rate : 0.00% (As of Mar. 2024)

View and export this data going back to . Start your Free Trial

What is Aspira Womens Health 3-Year Book Growth Rate?

Aspira Womens Health's Book Value per Share for the quarter that ended in Mar. 2024 was €-0.10.

During the past 12 months, Aspira Womens Health's average Book Value per Share Growth Rate was -211.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.

During the past 13 years, the highest 3-Year average Book Value per Share Growth Rate of Aspira Womens Health was 41.60% per year. The lowest was -58.30% per year. And the median was -14.15% per year.

Competitive Comparison of Aspira Womens Health's 3-Year Book Growth Rate

For the Diagnostics & Research subindustry, Aspira Womens Health's 3-Year Book Growth Rate, along with its competitors' market caps and 3-Year Book Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Aspira Womens Health's 3-Year Book Growth Rate Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Aspira Womens Health's 3-Year Book Growth Rate distribution charts can be found below:

* The bar in red indicates where Aspira Womens Health's 3-Year Book Growth Rate falls into.

Aspira Womens Health 3-Year Book Growth Rate Calculation

This is the 3-year average growth rate of Book Value per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.

Aspira Womens Health (FRA:CUL) 3-Year Book Growth Rate Explanation

Book Value per Share is the ratio of equity available to common shareholders divided by the shares outstanding. Book value per share effectively indicates a firm's net asset value on a per-share basis. It can be used by investors to gauge whether a stock price is undervalued by comparing it to the firm's market value per share. Theoretically, it is what the shareholders will receive if the company is liquidated.

Aspira Womens Health 3-Year Book Growth Rate Related Terms

Thank you for viewing the detailed overview of Aspira Womens Health's 3-Year Book Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Aspira Womens Health (FRA:CUL) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Aspira Womens Health Inc (FRA:CUL) » Definitions » 3-Year Book Growth Rate

Comparable Companies

DRIO OCX ENZ BIAF PRE TTOO XGN DMTK SLDX MYNZ TMO DHR IQV XSWX:LONN IDXX A MTD ICLR ILMN WAT

Traded in Other Exchanges

AWH:USA

Address

12117 Bee Caves Road, Suite 100, Building 3, Austin, TX, USA, 78738

Website

https://www.aspirawh.com

Aspira Womens Health Inc is engaged in developing and commercializing diagnostic tests for gynecologic diseases. The Company markets and sells, 1) Ova1, a blood test intended as an aid to assess the likelihood of malignancy in women with an ovarian adnexal mass for which surgery is planned when the physician's independent clinical and radiological evaluation does not indicate malignancy; (2) Overa, a second-generation biomarker reflex intended to maintain Ova1's high sensitivity while improving specificity; (3) Ova1Plus, a reflex offering which uses Ova1 as the primary test and Overa as a confirmation for Ova1 intermediate range results; and (4) OvaWatch, a lab-developed blood test intended to assist in the initial clinical assessment of malignancy risk in all women with an adnexal mass.

Aspira Womens Health (FRA:CUL) Headlines

No Headlines